The store will not work correctly when cookies are disabled.
4-(6-(pyridin-3-yl)pyrazolo[1,5-a]pyrimidin-3-yl)-N-(2,2,2-trifluoroethyl)thiophene-2-carboxamide
ID: ALA4550262
PubChem CID: 25205097
Max Phase: Preclinical
Molecular Formula: C18H12F3N5OS
Molecular Weight: 403.39
Molecule Type: Unknown
Associated Items:
Names and Identifiers
Canonical SMILES: O=C(NCC(F)(F)F)c1cc(-c2cnn3cc(-c4cccnc4)cnc23)cs1
Standard InChI: InChI=1S/C18H12F3N5OS/c19-18(20,21)10-24-17(27)15-4-12(9-28-15)14-7-25-26-8-13(6-23-16(14)26)11-2-1-3-22-5-11/h1-9H,10H2,(H,24,27)
Standard InChI Key: GDEGOXINVAEAGP-UHFFFAOYSA-N
Molfile:
RDKit 2D
28 31 0 0 0 0 0 0 0 0999 V2000
17.5655 -17.4582 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
17.5655 -18.2754 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
18.2708 -18.6798 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
18.2708 -17.0455 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
18.9760 -17.4582 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
18.9760 -18.2764 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
19.7542 -18.5293 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
20.2352 -17.8673 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
19.7542 -17.2054 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
20.0083 -19.3106 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
19.5279 -19.9717 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
20.0082 -20.6329 0.0000 S 0 0 0 0 0 0 0 0 0 0 0 0
20.7855 -20.3804 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
20.7854 -19.5633 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
21.4466 -20.8608 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
21.3612 -21.6735 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
22.1931 -20.5284 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
22.8543 -21.0087 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
23.6008 -20.6763 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
24.2619 -21.1567 0.0000 F 0 0 0 0 0 0 0 0 0 0 0 0
23.6862 -19.8636 0.0000 F 0 0 0 0 0 0 0 0 0 0 0 0
24.3052 -20.2606 0.0000 F 0 0 0 0 0 0 0 0 0 0 0 0
16.8590 -17.0538 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
16.8579 -16.2355 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
16.1499 -15.8290 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
15.4424 -16.2397 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
15.4474 -17.0612 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
16.1560 -17.4639 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
1 2 1 0
1 4 2 0
2 3 2 0
3 6 1 0
5 4 1 0
5 6 1 0
6 7 2 0
7 8 1 0
8 9 2 0
9 5 1 0
10 11 2 0
11 12 1 0
12 13 1 0
13 14 2 0
14 10 1 0
7 10 1 0
13 15 1 0
15 16 2 0
15 17 1 0
17 18 1 0
18 19 1 0
19 20 1 0
19 21 1 0
19 22 1 0
23 24 2 0
24 25 1 0
25 26 2 0
26 27 1 0
27 28 2 0
28 23 1 0
1 23 1 0
M END
Associated Targets(Human)
Molecule Features
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Unknown | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
Drug Indications
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanisms of Action
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Calculated Properties
Molecular Weight: 403.39 | Molecular Weight (Monoisotopic): 403.0715 | AlogP: 3.81 | #Rotatable Bonds: 4 |
Polar Surface Area: 72.18 | Molecular Species: NEUTRAL | HBA: 6 | HBD: 1 |
#RO5 Violations: ┄ | HBA (Lipinski): 6 | HBD (Lipinski): 1 | #RO5 Violations (Lipinski): ┄ |
CX Acidic pKa: 13.90 | CX Basic pKa: 4.55 | CX LogP: 2.67 | CX LogD: 2.67 |
Aromatic Rings: 4 | Heavy Atoms: 28 | QED Weighted: 0.56 | Np Likeness Score: -2.11 |
References
1. Sloman DL, Noucti N, Altman MD, Chen D, Mislak AC, Szewczak A, Hayashi M, Warren L, Dellovade T, Wu Z, Marcus J, Walker D, Su HP, Edavettal SC, Munshi S, Hutton M, Nuthall H, Stanton MG.. (2016) Optimization of microtubule affinity regulating kinase (MARK) inhibitors with improved physical properties., 26 (17): [PMID:27491711] [10.1016/j.bmcl.2016.02.003] |